ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Form 6-K — Sep 17, 2026
Ascentage Pharma reported first-half 2026 revenue of RMB302.2 million (US$44.5 million), up 29.3% on a constant-currency basis from RMB233.7 million a year earlier, driven by a 32.6% rise in product sales to RMB282.4 million as Lisaftoclax ramped post-launch and Olverembatinib held its cornerstone CML position. Net loss widened to RMB817.0 million (US$120.4 million) from RMB590.8 million in H1 2025, as total operating expenses grew 36.1% to RMB1,042.7 million, with R&D up 32.0% to RMB697.5 million on global registrational trials and selling expenses up 64.3% to RMB226.4 million to fund the Lisaftoclax launch.
Key figures
- Eps
- RMB(2.19) basic and diluted loss per share (H1 2025: RMB(1.73))
- Revenue
- RMB302.2 million (US$44.5 million) for H1 2026
- Net Income
- Net loss RMB817.0 million (US$120.4 million) vs RMB590.8 million (US$82.5 million) loss in H1 2025
- Revenue Yoy
- +29.3% (CER basis; +RMB68.5 million)
- Cash Position
- RMB1,895.6 million (US$279.4 million) at June 30, 2026, down 23.3% (CER) from RMB2,470.1 million (US$353.2 million) at Dec 31, 2025
- Rnd Expenses
- RMB697.5 million (US$102.8 million), +32.0% YoY
- Product Sales
- RMB282.4 million (US$41.6 million), +32.6% YoY
- Commercial Team
- nearly 300 staff covering approximately 1,500 hospitals in China
- Customer ARevenue
- RMB210.4 million, roughly 70% of total H1 2026 revenue
- Global CMLMarket Size
- US$12.3 billion (2023), projected US$14.6 billion by 2035
- Operating Cash Outflow
- RMB581.2 million (H1 2025: RMB432.1 million)
- Weighted Average Shares
- 373248217
- Global CLLSLLMarket Size
- approximately US$9.4 billion (2023), projected US$38.2 billion by 2035
- Total Comprehensive Loss
- RMB845.1 million (H1 2025: RMB591.8 million)
- Total Operating Expenses
- RMB1,042.7 million (US$153.7 million), +36.1% YoY
- Lisaftoclax Formulary Sites
- 415
- Olverembatinib Formulary Sites
- 879
- Selling And Distribution Expenses
- RMB226.4 million (US$33.4 million), +64.3% YoY
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.